Abstract:Neurodegenerative diseases are generally associated with impairments in mitochondrial function that lead to metabolic insufficiency, excitotoxicity and oxidative damage. The progression of Alzheimer's disease (AD) involves a number of mutually reinforcing factors including misprocessed amyloid precursor protein, metabolic insufficiency, inflammation, oxidative damage and excitotoxicity that ultimately concludes in neurodegeneration. Seizures also induce neurodegeneration by excitotoxicity. PN401 (triacetyluridine) is a uridine prodrug that enables oral bioavailability of> 100μM plasma uridine in humans. PN401 has been shown to improve memory in Tg2576 (APPswe) AD mice and improve motor performance and survival in R6/2 and N171-82Q (polyglutamine repeat) mice that model Huntington's disease (HD). These studies tested if PN401 treatment had an effect on neurodegeneration and oxidative stress in models of AD, HD, Parkinson's disease (PD) or excitotoxicity and if PN401 had antiepileptic activity. Neurodegeneration was assessed by silver and nissl stains. The number of degenerating neurons was quantified by counting silver positive cells from multiple brain sections. Lipid peroxidation was measured by TBARS method. PN401 was given in chow (6%) or p.o. 4g/kg b.i.d. Fibroblasts from AD or age-matched controls had reactive oxygen species (ROS) detected by fluorescent dye carboxy-H2DCFDA and cell death by LDH ratio. PN401 decreased neurodegeneration in the frontal cortex and hippocampus of 12 and 16-month old Tg2576 mice and 4-month old N171-82Q mice. 20-month old GFAP-IL-6 mice that overexpress IL-6 had an increased striatal and cortical neurodegeneration that was blocked by PN401. Kainic acid induced neurodegeneration and mortality was attenuated by PN401. MPTP induced striatal dopamine loss and mortality was attenuated by PN401. PN401 decreased liver lipid peroxidation due to LPS in Tg2576 and GFAP-IL-6 mice. PN401 decreased seizure severity and increased the latency to seizure due to pentylene tetrazole or 3-nitropropionic acid. Uridine dose-dependently (10-200μM) protected AD fibroblasts from chemical hypoxia (azide+ no glucose). Uridine dose-dependently decreases ROS due to H2O2 in AD fibroblasts. PN401 enables oral bioavailability of uridine at supraphysiological levels to achieve optimal therapeutic benefits. PN401 demonstrates neuroprotective activity in models of AD, HD, PD, excitotoxicity and has antiepileptic activity.

PN401 decreases neurodegeneration in models of Alzheimer’s, Huntington’s and Parkinson’s disease, neuroinflammation, excitotoxicity and has antiepileptic activity